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Abstract 
Review on IL7R, with data on DNA/RNA, on the 
protein encoded and where the gene is implicated. 
Identity 
Other names: CD127, CDW127, IL-7R-alpha, 
IL7RA, ILRA 




The gene is composed of 8 exons. The canonical 
transcript is 4619 bp long.  
Alternative splicing generates a soluble isoform 
lacking exon 6 and introducing a premature stop 





The precursor IL-7Rα protein includes a signal  
peptide (20 aminoacids) and has 459 aminoacids in 
total. The mature protein undergoes several post-
translational modifications including glycosylation 
(6 potential N-glycosylation sites in the 
extracellular domain) and dissulfide bond 
formation.  
The extracellular domain has 219 aminoacids 
(spanning from aminoacids 21 to 239), the 
transmembrane domain has 25 aminoacids 
(spanning from aminoacids 240 to 264), and the 
cytoplasmic tail spans from aminoacids 265 - 459 
(195 aminoacids).  
The soluble isoform of the receptor lacks the 
transmembrane domain (exon 6) and, due to an 
altered translation reading frame, it thereafter 
contains 27 unique aminoacids in the C-terminus 
(Goodwin et al., 1990; Rose et al., 2009). 
Expression 
IL-7Rα expression and signaling is required for 
normal T-cell development and homeostasis (Puel 
et al., 1998; Ribeiro et al., 2013).  
Although IL-7 signaling is not required for normal 
human B-cell development (in contrast to the 
mouse, where it is fundamental) IL-7Rα is also 




IL7R gene. The gene is composed of 8 exons highlighted in dark green. The 5' and 3' untranslated regions (UTR) are highlighted 
in light green. 
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IL-7Rα protein. This receptor belongs to the type-I cytokine receptor family. In the extracellular domain, it displays 4 paired 
cysteines (represented in yellow) in 2 fibronectin type III-like domains and, closer to the transmembrane domain, a WSxWS 
motif. The intracellular domain has a Box 1 motif and at least 2 tyrosines (Y401, Y449) involved in signal transduction (Lin et al., 
1995; Venkitaraman and Cowling, 1994). 
 
Localisation 
The functional protein is localized at the plasma 
membrane where it forms an heterodimeric 
complex with the common gamma chain (IL-2Rγ, 
CD132) to transduce IL-7 signaling or the cytokine 
receptor-like factor 2/ thymic stromal 
lymphopoietin receptor (CRLF2/TSLPR) to 
transduce TSLP signaling. IL-7Rα endocytosis via 
clathrin-coated pits appears to be required for 
maximal IL-7-mediated signaling (Henriques et al., 
2010). 
Function 
IL-7Rα mediates the signaling of IL-7 and TSLP 
cytokines. The cytoplasmic tail of IL-7R associates 
directly with JAK1 to transduce intracellular 
signaling together with JAK3 or JAK2 that are 
associated with the IL-2Rγ or TSLPR, respectively. 
The intracellular signaling pathways activated upon 
IL-7/IL-7R engagement in T-cells are the 
JAK/STAT (Lin et al., 1995; Rosenthal et al., 
1997), PI3K/Akt/mTOR (Dadi and Roifman, 1993; 
Venkitaraman and Cowling, 1994; Rathmell et al., 
2001) and, in some instances, MEK/Erk (Fleming 
and Paige, 2001; Maki and Ikuta, 2008; Patel and 
Chang, 2012). 
IL-7/IL-7R signaling is required for T-cell 
development at different stages. At the double-
negative stage (DN; CD4- CD8-), it is required for 
survival and proliferation of T-cells. It is also 
required to initiate the recombination of the TCRγ 
locus (Ye et al., 2001), the reason why it is 
absolutely required for γδ T-cell development. The 
receptor is down-regulated at the double-positive 
stage (DP; CD4+ CD8+) and up-regulated again at 
the single-positive stage (SP; CD4+ or CD8+). At 
this stage, IL-7R appears to be involved in CD4 
versus CD8 lineage specification (at least in the 
mouse, possibly in humans) and overall cell 
survival (Park et al., 2010; Sinclair et al., 2011). 
Mature T-cells also benefit from IL-7R signaling 
for homeostatic maintenance and function (Soares 
et al., 1998). 
The function of the TSLP/IL-7R signaling is much 
less known. Most studies, suggest an important role 
in the normal function of dendritic cells, immune  
tolerance and allergy (Watanabe et al., 2005; Lee et 
al., 2008; reviewed in Ziegler, 2012 and Hanabuchi 
et al., 2012). 
Homology 
IL-7R displays aminoacid sequence identity with 
other human cytokine receptors, such as IL-2R 
(14.6%), IL-6R (13.2%) GM-CSF receptor (16.0%) 
GH receptor (12.9%) (Goodwin et al., 1990). 
Orthologs of the human IL-7R are found in other 
species. The murine Il7r has 64%/67.2% 
DNA/protein identity (Goodwin et al., 1990) and 
the zebrafish il7r has 20.5% protein identity 




Hereditary recessive inactivating mutations in the 
IL7R gene have been found to cause severe 
combined immunodeficiency (SCID)(Puel et al., 
1998; Roifman et al., 2000; Jo et al., 2004; Gilian 
et al., 2005).  
The mutations occur in the extracellular domain 
coding region and comprise missense, nonsense 
mutations and splicing affecting mutations.  
The IL-7R SCID is characterized as T-B+NK+. The 
treatment is hematopoietic stem cell transplantation. 
Somatic 
Somatic and heterozygous IL7R gain-of-funtion 
gene mutations have been found in around 9-10% 
of childhood T-cell acute lymphoblastic leukemia 
(T-ALL) cases (Zenatti et al., 2011; Shochat et al., 
2011; Zhang et al., 2012).  
Later, mutations in the IL7R in adult T-ALL (1.7%) 
were also found (Kim et al., 2013). So far, all T-
ALL mutations described are restricted to exon 6, 
affecting the extracellular juxtamembrane-
transmembrane domain of the protein.  
The mutations are in-frame insertions or deletions-
insertions.  
The majority include an unpaired cysteine addition 
responsible for the homodimerization of two IL7-
Rα chains via disulphide bond formation.  
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IL-7Rα mutational hotspot for gain-of-function mutations. The figure depicts the 3 major domains of the IL-7R with the 
mutational hotspots present. The T-ALL mutations are restricted to exon 6 (coding for the transmembrane domain) and affect the 
juxtamembrane-transmembrane region (yellow lightning bolts). B-ALL mutations, although rarer, can also affect exon 5 (S185C; 
red lightning bolt). 
 
The dimerization of the receptor leads to ligand-
independent constitutive signaling via JAK1 
(Zenatti et al., 2011), contrasting with the 
physiological heterodimeric IL-7-dependent 
activation of the receptor that additionally requires 
IL-2Rγ and JAK3. 
IL7R somatic, heterozygous mutations have also 
been described in a small fraction of B-cell ALL 
(B-ALL) cases (less than 1%), significantly 
associated with aberrant TSLPR expression 
(Shochat et al., 2011). These included similar 
mutations to those found in T-ALL, as well as, in 
half of the cases, mutations in exon 5 leading to an 
S185C aminoacid substitution (Shochat et al., 
2011). 
Implicated in 
Severe combined immunodeficiency 
(SCID) 
Disease 
IL-7R SCID of T-B+NK+ type results from loss-of-
function mutations. For further details see the 
Mutations section. 
Prognosis 
IL-7R SCID is a fatal disease. The treatment is 
bone marrow transplantation. 
T-cell acute lymphoblastic leukemia 
(T-ALL) 
Prognosis 
IL7R mutations are not associated with prognosis 
(Zenatti et al., 2011). Increased IL-7 responsiveness 
in vitro was associated with better initial response 
to treatment in vivo (Karawajew et al., 2000). Low 
expression of IL-7R was found correlated with poor 
prognosis (Cleaver et al., 2010). 
Oncogenesis 
IL-7/IL-7R signaling has a major impact in the 
survival and proliferation of T-ALL cells in vitro 
(e.g. Touw et al., 1990; Dibirdik et al., 1991; Barat  
et al., 2004a; Barata et al., 2004b) and leukemia 
expansion in vivo (Silva et al., 2011). 
Oncogenic IL7R activating mutations occur in T-
ALL. See the Mutations section for details. 
Truncated forms of the IL-7R originated by 
alternative splicing were found in childhood T-ALL 
primary samples (Korte et al., 2000). The truncated 
receptors still bind IL-7 and it was postulated, but
not functionally demonstrated, that they might 
modulate IL-7 downstream signaling. 
B-cell acute lymphoblastic leukemia 
(B-ALL) 
Oncogenesis 
IL-7R mutations occur in B-ALL. See the 
Mutations section for details. 
Expression of survival and proliferation markers is 
associated with CD127+ B-ALLs vs CD127- B-
ALLs (Sasson et al., 2010). 
Chronic lymphocytic leukemia (CLL) 
Oncogenesis 
IL-7 mRNA was detected in a whole cohort of 20 
CLL primary samples (Frishman et al., 1993). 
IL-7 was found to induce proliferation of CLL 
primary samples (Digel et al., 1991). 
Acute myeloid leukemia (AML) 
Oncogenesis 
IL-7 was found to induce proliferation of AML 
primary samples (Digel et al., 1991). 
An Exon 6 mutation in the IL7R gene was found in 
one case of adult AML (Kim et al., 2013). The 
functional impact of this mutation, which does not 
conform to the T-ALL or B-ALL type of mutations, 
was not evaluated. 
Hodgkin's lymphoma (HL) 
Oncogenesis 
Both IL-7 and IL-7R proteins were found to be 
expressed in HL cell lines. An IL-7 autocrine loop 
was present that could sustain basal proliferation of 
these cells and the cells could further respond to 
exogenous added IL-7 (Cattaruzza et al., 2009). 
Cutaneous T-cell lymphoma (CTL) 
Oncogenesis 
Both IL-7 and IL-7R expression was found in CTL 
primary samples (Foss et al., 1994). All 7 samples 
analyzed proliferated in the presence of IL-7. There 
was evidence for a possible autocrine loop. 
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Breast cancer 
Oncogenesis 
Both IL-7 and IL-7R were found to be expressed in 
some breast cancer cases.  
Patients with poorer prognosis had higher 
expression of both genes in the cancer tissue than 
those with better prognosis (Al-Rawi et al., 2004). 
Colorectal cancer 
Oncogenesis 
IL-7 was found to be secreted in vitro by cultured 
colorectal cancer cell lines (2/4) and primary 
samples (16/18) (Maeurer et al., 1997). 
Mutations in the exon 6 of the IL7R (0.5%) were 
found in a cohort of primary samples (Kim et al., 
2013).  
However, these were frameshift mutations 
generating an early stop codon. Their functional 
impact was not evaluated. 
Esophageal cancer 
Oncogenesis 
The expression levels of a small array of 21 
cytokines in 6 esophageal cancer cell lines showed 
that IL-7 is expressed in 5 (Oka et al., 1995). 




Both IL-7 mRNA and protein were found to be 
secreted in renal carcinoma cell lines dependent on 
interferon gamma (IFNg) constitutive stimulation 
(Trinder et al., 1999). 
In another study, IL-7R mRNA was found 
expressed in 2/7 renal carcinoma cell lines 
(Cosenza et al., 2002). 
Lung cancer 
Prognosis 
High expression of IL-7R in tumor cells isolated 
from patients with stage I lung adenocarcinoma was 
predictive of poor overall outcome and increased 
probability of tumor recurrence (Suzuki et al., 
2013). 
Oncogenesis 
IL-7R mRNA and protein (3/7) were detected in 
lung cancer cell lines (Cosenza et al., 2002). 
A missense mutation in the exon 6 of the IL7R was 
found in a member (0.6%) of a cohort of primary 
non-small cell lung cancer samples (Kim et al., 
2013).  
The mutation does not conform to the type of 
mutations found in T-ALL or B-ALL.  
The functional impact of this mutation, which is 




A single nucleotide polymorphism at position 
244(T/I) is associated with increased risk of mutiple 
sclerosis. T244 promotes increased exon 6 skipping 
leading to higher production of soluble IL7-Ra 
(Lundmark et al., 2007; Hafler et al., 2007). The 




The 244(T/I) polymorphism was also found to be 
associated with rheumatoid arthritis risk (O'Doherty 
et al., 2009). 
Omenn syndrome (OS) 
Disease 
A patient with OS, a SCID syndrome with graft-
vesus-host disease symptoms, was found to have a 
mutation (C118Y) in the IL-7R (Giliani et al., 
2006). This mutation was previously found 
correlated with SCID (Giliani et al., 2005). 
Allogeneic stem cell transplantation 
(SCT) 
Note 
The single nucleotide polymorphism (SNPs) IL7Ra 
+1237 A/G (position) in the donors for SCT was 
found to correlate with survival of the recipient 
after SCT (Shamim et al., 2006). 
HIV infection 
Disease 
Although the effects of IL-7/IL-7R during HIV 
infection on T-cells are well established, they are
complex and still under heavy investigation. This 
entry only superficially covers some aspects of this
relationship. 
During HIV infection, T-cells have decreased IL-
7R expression compared to healthy controls as well 
as decreased responsiveness to IL-7 (Carini et al., 
1994; Vingerhoets et al., 1998). 
The HIV Tat protein was found to be responsible 
for the downregulation of the receptor in CD8 T-
cells (Faller et al., 2006). 
The soluble IL-7R is increased in HIV+ individuals 
and can decrease the IL-7 activity in CD8 T-cells 
(Crawley et al., 2010). 
Administration of IL-7 to HIV+ individuals under 
anti-retroviral therapy leads to an expansion of the 
T-cell compartment (Sereti et al., 2009; Levy et al., 
2009) which may help to restore normal T-cell 
levels, however increased persistence of the virus in 
the affected individuals during therapy 
(Vandergeeten et al., 2013) may raise some 
concerns regarding the IL-7 therapy. 
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Comprehensive reviews on this topic include, but 
are not restricted to: Crawley and Angel, 2012; 
Sieg, 2012. 
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